AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

75 76 Next >

UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments ↗

October 10, 2025

UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies.

Via Benzinga

Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation

October 09, 2025

New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...

Via MarketMinute

Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds

October 09, 2025

New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...

Via MarketMinute

Topics Economy Intellectual Property Retirement

AstraZeneca Announces $4.5B Investment In Virginia ↗

October 09, 2025

Via Stocktwits

AstraZeneca Plans Ordinary Share Listing In US – Find Out More On The Harmonized Listing Structure ↗

September 29, 2025

Via Stocktwits

AstraZeneca Expands Virginia Investment To $4.5 Billion For Cancer, Obesity Drugs ↗

October 09, 2025

AstraZeneca will invest $4.5 billion in a Virginia facility, creating 3,600 jobs and producing advanced cancer and metabolic medicines using AI and automation.

Via Benzinga

Topics Artificial Intelligence

Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch ↗

October 09, 2025

Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers.

Via Benzinga

Topics Government

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs

October 09, 2025

From AstraZeneca

Via Business Wire

A Look Into AstraZeneca Inc's Price Over Earnings ↗

October 09, 2025

Via Benzinga

Should You Forget Nvidia and Buy These 2 Millionaire-Maker Stocks Instead? ↗

October 09, 2025

These two up-and-coming tech stocks just might make investors more money over the next decade than Nvidia will.

Via The Motley Fool

Topics Artificial Intelligence

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension ↗

October 07, 2025

AstraZeneca's Baxdrostat cut 24-hour systolic blood pressure in a Phase 3 trial, showing promise for treatment-resistant hypertension patients.

Via Benzinga

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

October 07, 2025

From AstraZeneca

Via Business Wire

Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices ↗

October 06, 2025

Amgen launches AmgenNow, offering Repatha at $239 per month, expanding direct access for U.S. patients with no insurer restrictions.

Via Benzinga

Topics Government

AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases ↗

October 06, 2025

Algen Biotechnologies partners with AstraZeneca in a $555 million deal to advance AI-driven CRISPR drug discovery and novel immunology therapies.

Via Benzinga

Topics Artificial Intelligence

AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy ↗

October 06, 2025

AstraZeneca and Daiichi Sankyo's Datroway improved survival outcomes over chemotherapy in advanced triple-negative breast cancer patients.

Via Benzinga

Are Pure Play Quantum Computing Stocks a Buy in October? ↗

October 06, 2025

Quantum stocks have mooned in 2025, raising questions about whether their sky-high valuations reflect real breakthroughs or just speculation.

Via The Motley Fool

DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02

October 06, 2025

From AstraZeneca

Via Business Wire

FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape

October 03, 2025

In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca...

Via MarketMinute

Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors

October 04, 2025

As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for...

Via MarketMinute

Topics Artificial Intelligence Climate Change Economy

2 Under-The-Radar Health-Tech Stocks With Surging Momentum Scores ↗

October 03, 2025

Two under-the-radar health-tech stocks are seeing their Momentum scores surge in Benzinga's Edge Stock Rankings.

Via Benzinga

Investing in These 3 Quantum Computing Stocks Could Be a Once-in-a-Lifetime Opportunity ↗

October 03, 2025

All of these rising quantum computing stars could be massive winners over the long run.

Via The Motley Fool

Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings

October 02, 2025

Thousand Oaks, CA – October 2, 2025 – Amgen (NASDAQ: AMGN) has witnessed a robust surge in its share price, climbing approximately 6% in recent trading sessions, culminating on October 2, 2025, to...

Via MarketMinute

Topics Economy Intellectual Property Stocks

AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy? ↗

October 02, 2025

The uncertainty about U.S. pharmaceutical tariffs shouldn't be as worrisome for AstraZeneca now.

Via The Motley Fool

Topics Government World Trade

Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape

September 30, 2025

September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

Via Benzinga

Topics ETFs

AstraZeneca's Strategic Listing Harmonization: A Unified Global Platform for Growth

September 29, 2025

AstraZeneca (LSE: AZN, NASDAQ: AZN) has announced a significant strategic move to harmonize its stock market listings across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York...

Via MarketMinute

Topics Economy

GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley ↗

September 29, 2025

Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern.

Via Investor's Business Daily

AstraZeneca Moves From ADRs To NYSE Listing ↗

September 29, 2025

The Board of AstraZeneca plc (NASDAQ: AZN) is recommending to shareholders a Harmonized Listing Structure for the company's ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm...

Via Benzinga

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial

September 29, 2025

From AstraZeneca

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.